Interleukin 12 gene therapy - Regulon

Drug Profile

Interleukin 12 gene therapy - Regulon

Alternative Names: LipoVIL12

Latest Information Update: 30 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Regulon
  • Class Antineoplastics; Cytokine genes; Gene therapies; Interleukins
  • Mechanism of Action Immunomodulators; Interleukin 12 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Glioblastoma

Most Recent Events

  • 30 Sep 2015 Discontinued - Phase-I/II for Glioblastoma in Germany (Parenteral)
  • 30 Sep 2015 Discontinued - Phase-II for Glioblastoma in Greece (Parenteral)
  • 08 Dec 2014 Interleukin 12 gene therapy licensed to In Ovations Holdings
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top